Wall Street brokerages expect Charles River Laboratories Intl. Inc (NYSE:CRL) to announce $1.56 earnings per share for the current quarter, Zacks Investment Research reports. Eight analysts have issued estimates for Charles River Laboratories Intl.’s earnings. The highest EPS estimate is $1.61 and the lowest is $1.52. Charles River Laboratories Intl. posted earnings of $1.62 per share during the same quarter last year, which suggests a negative year-over-year growth rate of 3.7%. The company is scheduled to report its next quarterly earnings results on Wednesday, August 14th.

On average, analysts expect that Charles River Laboratories Intl. will report full year earnings of $6.48 per share for the current year, with EPS estimates ranging from $6.46 to $6.50. For the next financial year, analysts expect that the business will report earnings of $7.35 per share, with EPS estimates ranging from $7.14 to $7.55. Zacks Investment Research’s EPS averages are an average based on a survey of sell-side analysts that that provide coverage for Charles River Laboratories Intl..

Charles River Laboratories Intl. (NYSE:CRL) last released its quarterly earnings results on Tuesday, May 7th. The medical research company reported $1.40 earnings per share for the quarter, beating the Zacks’ consensus estimate of $1.38 by $0.02. The business had revenue of $604.57 million during the quarter, compared to analyst estimates of $587.65 million. Charles River Laboratories Intl. had a net margin of 9.63% and a return on equity of 23.03%. The business’s revenue was up 22.4% on a year-over-year basis. During the same period last year, the business earned $1.29 EPS.

A number of equities research analysts recently weighed in on the stock. Zacks Investment Research lowered shares of Charles River Laboratories Intl. from a “buy” rating to a “hold” rating in a report on Tuesday, April 16th. SunTrust Banks raised their price target on shares of Charles River Laboratories Intl. to $151.00 and gave the company a “buy” rating in a report on Thursday, February 14th. Evercore ISI reaffirmed an “outperform” rating and set a $160.00 price target on shares of Charles River Laboratories Intl. in a report on Tuesday, April 30th. Barclays reaffirmed a “hold” rating and set a $135.00 price target on shares of Charles River Laboratories Intl. in a report on Thursday, February 14th. Finally, Wolfe Research assumed coverage on shares of Charles River Laboratories Intl. in a report on Tuesday, April 2nd. They set a “market perform” rating for the company. Seven analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus target price of $145.64.

In other Charles River Laboratories Intl. news, CFO David Ross Smith sold 4,000 shares of the firm’s stock in a transaction on Monday, February 25th. The shares were sold at an average price of $145.43, for a total transaction of $581,720.00. Following the completion of the transaction, the chief financial officer now directly owns 24,262 shares of the company’s stock, valued at approximately $3,528,422.66. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, CEO James C. Foster sold 3,000 shares of the firm’s stock in a transaction on Monday, February 25th. The stock was sold at an average price of $146.02, for a total transaction of $438,060.00. Following the transaction, the chief executive officer now directly owns 286,397 shares of the company’s stock, valued at $41,819,689.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 36,570 shares of company stock valued at $5,152,105. 1.80% of the stock is owned by company insiders.

Hedge funds have recently made changes to their positions in the business. Tompkins Financial Corp grew its holdings in Charles River Laboratories Intl. by 63.1% during the 1st quarter. Tompkins Financial Corp now owns 199 shares of the medical research company’s stock worth $27,000 after acquiring an additional 77 shares in the last quarter. Fort L.P. acquired a new position in shares of Charles River Laboratories Intl. in the 4th quarter valued at about $27,000. Sageworth Trust Co acquired a new position in shares of Charles River Laboratories Intl. in the 1st quarter valued at about $37,000. Riverview Trust Co acquired a new position in shares of Charles River Laboratories Intl. in the 4th quarter valued at about $30,000. Finally, Cresset Asset Management LLC acquired a new position in shares of Charles River Laboratories Intl. in the 1st quarter valued at about $47,000. 93.90% of the stock is owned by institutional investors.

CRL opened at $129.08 on Friday. The firm has a market cap of $6.42 billion, a P/E ratio of 21.41, a PEG ratio of 1.69 and a beta of 0.99. Charles River Laboratories Intl. has a twelve month low of $103.00 and a twelve month high of $149.07. The company has a quick ratio of 1.39, a current ratio of 1.63 and a debt-to-equity ratio of 1.10.

About Charles River Laboratories Intl.

Charles River Laboratories International, Inc, an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services worldwide. It operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing).

Featured Article: Strike Price

Get a free copy of the Zacks research report on Charles River Laboratories Intl. (CRL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Charles River Laboratories Intl. (NYSE:CRL)

Receive News & Ratings for Charles River Laboratories Intl. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Charles River Laboratories Intl. and related companies with MarketBeat.com's FREE daily email newsletter.